CALT News and Press, Calliditas Therapeutics AB From 01/07/24

Calliditas to present at JP Morgan Healthcare Conference PR Newswire STOCKHOLM , Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the...

2023-12-27 13:25:53 ET Calliditas Therapeutics ( NASDAQ: CALT ) said Friday it has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management LP. Proceeds from the loan will primarily be utilized for full repayment of the company's e...

Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital PR Newswire STOCKHOLM , Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today an...

2023-12-21 11:11:40 ET More on Calliditas Therapeutics Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (Maintaining Buy) Calliditas partner wins China nod for kidney disease therapy Calliditas stock dips as losses widen in Q3 Seekin...

2023-12-21 10:08:45 ET U.S. stocks on Thursday gained , with markets rebounding from their worst sell-off since late September. Wall Street in the previous session slid more than 1% after a seven-week bull run, in a decline that was chalked up to overbought territory and zero-day option...

2023-12-21 08:33:51 ET Infrared Cameras Holdings  ( MSAI ) +140% . Shengfeng Development  ( SFWL ) +40% . Annexon  ( ANNX ) +39% stock jumps on pricing of $125M public offering of common stock. ParaZero Technologies ( PRZO ) +33% ...

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function PR Newswire STOCKHOLM , Dec. 20, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nas...

Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® PR Newswire STOCKHOLM , Dec. 11, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it h...

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome PR Newswire STOCKHOLM , Nov. 30, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced the initiation of a Ph...